Laurus Labs Ltd (NSE: LAURUSLABS) and Zydus Lifesciences Ltd (NSE: ZYDUSLIFE) are both listed in the Medicinal Chemicals and Botanical Products industry. Laurus Labs has a market capitalisation of ₹1,26,865 Cr and Zydus Lifesciences ₹1,23,740 Cr, as of 9 Nov 2026. Their P/E ratios are 142.7 and 24.8 respectively. Return on equity is 17.74% for Laurus Labs and 18.32% for Zydus Lifesciences. Over one year, Laurus Labs's share price is up 151.6% and Zydus Lifesciences's is up 23.9%.
| Metric | Laurus Labs | Zydus Lifesciences |
|---|---|---|
| NSE Symbol | LAURUSLABS | ZYDUSLIFE |
| BSE Code | 540222 | 532321 |
| Share Price | ₹2,454.00 | ₹1,215.90 |
| Market Cap | ₹1,26,865 Cr | ₹1,23,740 Cr |
| P/E Ratio | 142.7 | 24.8 |
| Return on Equity | 17.74% | 18.32% |
| Return on Assets | 8.18% | 8.13% |
| Dividend Yield | 0.10% | 0.08% |
| Beta (1Y) | 0.47 | 0.24 |
| 1-Year Price Change | +151.6% | +23.9% |
| 3-Month Price Change | +32.4% | +8.7% |
| 52-Week Range | ₹944.90 – ₹2,480.00 | ₹835.50 – ₹1,266.60 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹2,206 Cr | ₹7,910 Cr |
| Quarterly Net Profit | ₹436 Cr | ₹928 Cr |
| Net Margin | 19.8% | 11.7% |
| EPS (Basic, Quarter) | ₹8.17 | ₹9.28 |
| Results Basis | consolidated | consolidated |
| Headquarters | Hyderabad, Telangana | Ahmedabad, Gujarat |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. In addition, the company develops novel enzymatic solutions fo…
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pipeline of biological products in the areas of onco…
Laurus Labs has a market capitalisation of ₹1,26,865 Cr, against ₹1,23,740 Cr for Zydus Lifesciences as of 9 Nov 2026, so the two are about the same size by market cap.
Laurus Labs has a P/E of 142.7 and Zydus Lifesciences a P/E of 24.8 as of 9 Nov 2026.
Laurus Labs has a return on equity of 17.74% and Zydus Lifesciences 18.32%.
Laurus Labs's share price is up 151.6% over one year and Zydus Lifesciences's is up 23.9%.
Laurus Labs reported revenue of ₹2,206 Cr and net profit of ₹436 Cr for Q2 FY27. Zydus Lifesciences reported revenue of ₹7,910 Cr and net profit of ₹928 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.